Fayez Sarofim & Co Sells 2,870 Shares of Kenvue Inc. (NYSE:KVUE)

Fayez Sarofim & Co lowered its position in Kenvue Inc. (NYSE:KVUE) by 18.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,309 shares of the company’s stock after selling 2,870 shares during the quarter. Fayez Sarofim & Co’s holdings in Kenvue were worth $263,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in KVUE. Grove Bank & Trust increased its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue in the fourth quarter worth approximately $29,000. SRS Capital Advisors Inc. raised its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC lifted its position in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after buying an additional 1,441 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock opened at $22.29 on Tuesday. The stock has a market capitalization of $42.77 billion, a price-to-earnings ratio of 42.06, a PEG ratio of 2.62 and a beta of 1.02. The firm’s 50-day moving average price is $22.93 and its two-hundred day moving average price is $22.41. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.68%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price for the company. Barclays reduced their price target on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, April 14th. Finally, UBS Group cut their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.